Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Multicenter, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered FHD-286, as Monotherapy or Combination Therapy, in Subjects With Advanced Hematologic Malignancies

Next Previous
X
Search
Trial Profile

A Phase 1, Multicenter, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered FHD-286, as Monotherapy or Combination Therapy, in Subjects With Advanced Hematologic Malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FHD-286 (Primary) ; Cytarabine; Decitabine
  • Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Haematological malignancies; Myelodysplastic syndromes
  • Focus Adverse reactions; First in man
  • Sponsors Foghorn Therapeutics

    • Most Recent Events

    • 08 Aug 2024 According to a Foghorn Therapeutics media release, company anticipate topline data from this Phase 1 combination trial with FHD-286 in patients with relapsed and/or refractory AML in the fourth quarter of 2024. Company anticipate this will include topline safety, tolerability, initial efficacy and PK/PD data.
    • 06 May 2024 According to a Foghorn Therapeutics media release, initial data expected in second half of the year.
    • 12 Dec 2023 Results(As of 02 Aug 2022, n=40 patients) presented at the 65th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top